An assessment of antiviral drugs for the management of infectious diseases in humans
Identifieur interne : 002834 ( Main/Exploration ); précédent : 002833; suivant : 002835An assessment of antiviral drugs for the management of infectious diseases in humans
Auteurs : George J. Galasso [États-Unis]Source :
- Antiviral Research [ 0166-3542 ] ; 1981.
English descriptors
- Teeft :
- Abrupt onset, Adenine, Adenine arabinoside, Adenine arabinoside monophosphate, Adenine arabinoslde, Adenine arabinoslde monophosphate, Adenine arabmoside, Adenine arabmoslde, Adenine arabmoslde monophosphate, Amantadine, Antiviral, Antiviral agent, Antiviral agents, Antiviral drugs, Antivlral, Antivlral agents, Antlvlral agents, Arabinoside, Arabinoslde, Arabmoslde, Ascorbic acid, Beneficial effects, Beneficial role, Best results, Biomedical press, Brain tissue, Carrier rate, Chmcal study, Chnical, Clinical efficacy, Clinical studies, Collaborative study, Conclusive evidence, Core antigen, Corneal ulceration, Cytosine arabinoslde, Dane particles, Definitive study, Dos, Dosage, Drug therapy, Early promise, Echo viruses, Efficacy, Encephalitis, Etiological agent, Exciting results, Exogenous interferon, Genital herpes, Government authorities, Hepatitis, Herpes, Herpes encephalitis, Herpes genitalis, Herpes labialis, Herpes simplex, Herpes simplex virus, Herpes simplex virus type, Herpes viruses, Herpes zoster, High risk, Historic controls, Infection, Influenza, Influenza epidemics, Influenza pneumonia, Influenza viruses, Interferon, Lassa fever, Liver biopsy, Major problem, Monophosphate, Mortahty rate, Mortality rate, Neonatal herpes, Ocular herpes, Ointment, Older patients, Open studies, Ophthalmic ointment, Ophthalmic solution, Other agents, Other drugs, Other studies, Partial reduction, Personal communication, Petrolatum base, Placebo, Placebo group, Placebo groups, Pregnant women, Primary refection, Prophylaxis, Rapid clearance, Raven press, Recurrence, Recurrence rate, Refection, Renal function, Respiratory disease, Rhinovirus, Rhinovirus infections, Rhinovirus type, Rimantadine, Several agents, Shortest time, Side effects, Simplex, Such agents, Surface antigen, Therapeutic effect, Therapeutic efficacy, Topical treatment, Toxic level, Toxicity, Vaccine, Viral, Viral diseases, Viral infections, Virus, Zoster.
Url:
DOI: 10.1016/0166-3542(81)90035-8
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001402
- to stream Istex, to step Curation: 001402
- to stream Istex, to step Checkpoint: 001448
- to stream Main, to step Merge: 002981
- to stream Main, to step Curation: 002834
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>An assessment of antiviral drugs for the management of infectious diseases in humans</title><author><name sortKey="Galasso, George J" sort="Galasso, George J" uniqKey="Galasso G" first="George J." last="Galasso">George J. Galasso</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:5B16ABB788D66804F28AADB9F02251C61DB44691</idno><date when="1980" year="1980">1980</date><idno type="doi">10.1016/0166-3542(81)90035-8</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-5WX34SM5-3/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001402</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001402</idno><idno type="wicri:Area/Istex/Curation">001402</idno><idno type="wicri:Area/Istex/Checkpoint">001448</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001448</idno><idno type="wicri:doubleKey">0166-3542:1980:Galasso G:an:assessment:of</idno><idno type="wicri:Area/Main/Merge">002981</idno><idno type="wicri:Area/Main/Curation">002834</idno><idno type="wicri:Area/Main/Exploration">002834</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">An assessment of antiviral drugs for the management of infectious diseases in humans</title><author><name sortKey="Galasso, George J" sort="Galasso, George J" uniqKey="Galasso G" first="George J." last="Galasso">George J. Galasso</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>National Institutes of Health, Westwood Building, Room 750, Bethesda, MD 20205</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Antiviral Research</title><title level="j" type="abbrev">AVR</title><idno type="ISSN">0166-3542</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1981">1981</date><biblScope unit="volume">1</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="73">73</biblScope><biblScope unit="page" to="96">96</biblScope></imprint><idno type="ISSN">0166-3542</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0166-3542</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Abrupt onset</term><term>Adenine</term><term>Adenine arabinoside</term><term>Adenine arabinoside monophosphate</term><term>Adenine arabinoslde</term><term>Adenine arabinoslde monophosphate</term><term>Adenine arabmoside</term><term>Adenine arabmoslde</term><term>Adenine arabmoslde monophosphate</term><term>Amantadine</term><term>Antiviral</term><term>Antiviral agent</term><term>Antiviral agents</term><term>Antiviral drugs</term><term>Antivlral</term><term>Antivlral agents</term><term>Antlvlral agents</term><term>Arabinoside</term><term>Arabinoslde</term><term>Arabmoslde</term><term>Ascorbic acid</term><term>Beneficial effects</term><term>Beneficial role</term><term>Best results</term><term>Biomedical press</term><term>Brain tissue</term><term>Carrier rate</term><term>Chmcal study</term><term>Chnical</term><term>Clinical efficacy</term><term>Clinical studies</term><term>Collaborative study</term><term>Conclusive evidence</term><term>Core antigen</term><term>Corneal ulceration</term><term>Cytosine arabinoslde</term><term>Dane particles</term><term>Definitive study</term><term>Dos</term><term>Dosage</term><term>Drug therapy</term><term>Early promise</term><term>Echo viruses</term><term>Efficacy</term><term>Encephalitis</term><term>Etiological agent</term><term>Exciting results</term><term>Exogenous interferon</term><term>Genital herpes</term><term>Government authorities</term><term>Hepatitis</term><term>Herpes</term><term>Herpes encephalitis</term><term>Herpes genitalis</term><term>Herpes labialis</term><term>Herpes simplex</term><term>Herpes simplex virus</term><term>Herpes simplex virus type</term><term>Herpes viruses</term><term>Herpes zoster</term><term>High risk</term><term>Historic controls</term><term>Infection</term><term>Influenza</term><term>Influenza epidemics</term><term>Influenza pneumonia</term><term>Influenza viruses</term><term>Interferon</term><term>Lassa fever</term><term>Liver biopsy</term><term>Major problem</term><term>Monophosphate</term><term>Mortahty rate</term><term>Mortality rate</term><term>Neonatal herpes</term><term>Ocular herpes</term><term>Ointment</term><term>Older patients</term><term>Open studies</term><term>Ophthalmic ointment</term><term>Ophthalmic solution</term><term>Other agents</term><term>Other drugs</term><term>Other studies</term><term>Partial reduction</term><term>Personal communication</term><term>Petrolatum base</term><term>Placebo</term><term>Placebo group</term><term>Placebo groups</term><term>Pregnant women</term><term>Primary refection</term><term>Prophylaxis</term><term>Rapid clearance</term><term>Raven press</term><term>Recurrence</term><term>Recurrence rate</term><term>Refection</term><term>Renal function</term><term>Respiratory disease</term><term>Rhinovirus</term><term>Rhinovirus infections</term><term>Rhinovirus type</term><term>Rimantadine</term><term>Several agents</term><term>Shortest time</term><term>Side effects</term><term>Simplex</term><term>Such agents</term><term>Surface antigen</term><term>Therapeutic effect</term><term>Therapeutic efficacy</term><term>Topical treatment</term><term>Toxic level</term><term>Toxicity</term><term>Vaccine</term><term>Viral</term><term>Viral diseases</term><term>Viral infections</term><term>Virus</term><term>Zoster</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Galasso, George J" sort="Galasso, George J" uniqKey="Galasso G" first="George J." last="Galasso">George J. Galasso</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002834 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002834 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:5B16ABB788D66804F28AADB9F02251C61DB44691
|texte= An assessment of antiviral drugs for the management of infectious diseases in humans
}}
| This area was generated with Dilib version V0.6.33. |  |